alexa Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

International summit on Herbal and Traditional medicine

Tokyo, Japan

Advancement in Drug Discovery

New York, USA
Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBD) are common group of digestive inflammatory disorder, which characterized defective regulation of adaptive immunity. There are raised evidences that intercellular cooperation affected epithelial cells, macrophages and dendritic cells play a pivotal role in gut homeostasis. Therefore, dysregulation of cell cooperation may lead to decreased epithelial integrity and worsening of IBD.


Recent pre-clinical and clinical investigations have shown that micro RNAs are involved in several pathological processes affected cell-to-cell cooperation, transferring information, tissue repair mediating, angiogenesis and neo-vascualrization. The mini review is discussed the potential role of micro RNAs as biomarkers and tool for target-based treatment in patients with inflammatory bowel diseases. Ulcerative colitis (UC) and Crohn's disease (CD) are the most frequently seen inflammatory bowel diseases (IBD), which have similar morphopathogenesis, but they are recognized as diseases that are distinguished sites affected the gastrointestinal tract and outside areas. Although prevalence rates of IBD is variant in different countries, the chronic relapsing-remitting inflammatory disorders affecting primarily the gastrointestinal tract arises worldwide.


In fact, the importance of genetic risk factors in IBD development is high and it has been documented more clearly for CD than for UC [4]. Moreover, genetic risk factors added to age-related factors, female gender, obesity, current symptoms, and histopathology stages significantly associated with a reduced quality of life, body image dissatisfaction, and disability. Therefore, patients with IBM are at significant higher risk for colorectal dysplasia, cancer, bleeding, cachexia, as well as extra intestinal manifestations, such as rheumatoid arthritis.


For related articles:

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger